Glenmark initiates myeloma drug trial
08 December 2017 | News
GBR 1342 is an investigational new drug from the company's immuno-oncology portfolio.
Image credit- covance blog
Glenmark Pharma has initiated the phase-1 clinical trial of GBR 1342, an investigational antibody for treatment of multiple myeloma.
GBR 1342 is an investigational new drug from the company's immuno-oncology portfolio.
Glenmark had received clearance from US health regulator in May this year, for the investigational new drug application to initiate phase-1 study of GBR 1342.
This first-in-human, open-label study's primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached.
The additional study objectives include assessment of biomarkers, immunogenicity and additional measures of anti- tumour activity.
